The male infertility pharmaceutical market across the seven major markets (7MM: US, 5EU, and Japan) is projected to grow at a compound annual growth rate (CAGR) of 2.9% between 2025 and 2035, driven primarily by rising awareness of male reproductive health and continued population growth, according to GlobalData, a leading intelligence and productivity platform.

GlobalData’s report “Male Infertility: Disease Analysis and Forecast,” reveals that of the pipeline therapeutics, pentoxifylline is the most likely to reach the market in the forecast period. However, the overall impact on the market will be minimal, with estimated sales of only $179,660 in the 7MM in 2035. It is unlikely to displace the existing therapeutic options.

David Beauchamp, Pharma Analyst at GlobalData, comments: “The patient population for male infertility therapeutics will grow commensurate with the overall population in the 7MM. Novel therapeutics are unlikely to affect the growth of the market in the forecast period with any significance. There is a severe lack of understanding of the mechanisms causing male infertility, and clinical trials are sparse and poorly funded. Pharmacological therapies also must compete against proven fertility methods, such as assisted reproductive technologies (ART).”

The existing therapeutic options for male infertility in 2025 include gonadotropins such as menotropin, chorionic gonadotropin, and urofollitropin; clomiphene citrate, a selective estrogen receptor modulator; and Mesterolone, an androgen receptor agonist. All these drugs are available as generic therapies.

Beauchamp concludes: “The male infertility therapeutics market is expected to experience steady growth through 2035, supported by increasing awareness of male reproductive health and a growing patient population across the 7MM. However, the market’s evolution will remain constrained by the limited number of novel pipeline therapies and the continued reliance on ARTs. Greater understanding of the underlying causes of male infertility and increased investment in therapeutic development will be essential to unlock stronger long-term growth opportunities in this space.”